Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

KYTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Kyverna Therapeutics, Inc.NASDAQ: KYTX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 60.43M shares rose 39.8% year over year, ahead of the +12.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 28.2% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +39.8% holds above the trailing-twelve-month pace of +12.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
60.43M+28.2% QoQ
Last fiscal yearDec 2025
44.26M+15.5% YoY
LTMMar 2026
48.56M+12.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.8%——
1 year+15.5%——
3-year CAGR+19.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
44.26M USD
Year-over-year change
+15.5%
4-year CAGR
+14.4%

Weighted Avg Shares (Diluted) vs competitors

How KYTX compares with its peers on the latest reported figures

  • KYTX's LTM Mar 2026 weighted avg shares (diluted) of 48.56M shares is the 8th highest of the 11 companies compared; the peer median is 72.78M shares.
  • Its year-over-year change of +12.5% is the 6th highest of 10, against a peer median of +18.4%.
  • Over three fiscal years its annual growth of +19.7% compares with a peer median of +13.5%.
KYTX Competitors Peer median
Weighted Avg Shares (Diluted) for KYTX and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
MREOMereo BioPharma Group plcLTM Mar 2026159.92M +5.1%+9.7%
CABACabaletta Bio, Inc.LTM Mar 202694.61M +90.6%+51.6%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
SLNSilence Therapeutics plcLTM Mar 202631.49M —+63.9%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
Peer median (excluding KYTX) 72.78M+18.4%+13.5%

Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.66M7.03M000
Cost of Revenue001.71M2.13M0
Gross Profit5.66M7.03M(1.71M)(2.13M)0
Gross Margin100.0%100.0%———
Research & Development25.85M28.4M48.22M112.47M133.72M
Selling, General & Admin6.15M8.01M12.48M30.13M36.11M
Operating Expenses32M36.41M60.7M140.47M169.83M
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
EBITDA(25.76M)(27.78M)(58.47M)(125.2M)(159.02M)
EBITDA Margin-455.5%-395.4%———
Operating Income(26.35M)(29.38M)(62.41M)(142.6M)(169.83M)
Operating Margin-465.8%-418.3%———
Interest Income1K565K2.28M15.36M9.09M
Interest Expense3K65K187K142K489K
Other Income / Expenses(4K)491K2.04M15.13M8.52M
Income Before Tax(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Pre-Tax Margin-465.9%-411.3%———
Income Tax Expense00000
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Net Margin-465.9%-411.3%———
EPS (Basic)(1.02)(1.12)(0.00)(3.33)(3.64)
EPS (Diluted)(1.02)(1.12)(0.00)(3.33)(3.64)
Weighted Avg Shares25.8M25.8M673.62M38.33M44.26M
Weighted Avg Shares (Diluted)25.8M25.8M673.62M38.33M44.26M

Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Intrinsic Alpha fair value

Locked

Current Price

$4.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.